SPPI News and Press, Spectrum Pharmaceuticals Inc. From 08/06/21

Shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) were crashing 26.3% lower as of 11:14 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving canc...

Boston, Massachusetts--(Newsfile Corp. - August 6, 2021) - Block & Leviton is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who have lost money in their Spectrum Pharmaceuticals investment should contact the firm to learn m...

Spectrum Pharmaceuticals SPPI -35% after FDA declines to approve ROLONTIS Dicerna Pharmaceuticals DRNA -28% slide despite pivotal nedosiran study hitting primary endpoint Zynga ZNGA -16% on Q2 earnings release Chembio Diagnostics CEMI -13% on Q2 earning...

The U.S. FDA has declined to approve Spectrum Pharmaceuticals' (NASDAQ:SPPI) ROLONTIS (eflapegrastim) for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs. Shares down more than 24% premarket. The FDA's complete response letter cited de...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Applic...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2021 financial results and provide a corporate update on Thursday, August 12, 2021 at 4:3...

BYSI has a November PDUFA for plinabulin in chemo-induced neutropenia. There are certain ways in which plinabulin and Spectrum's rolontis complement each other. Below is an overview of plinabulin and a comparison. For further details see: BeyondSpring's Plinabulin: Upcom...

The FDA completed the inspection of Hanmi's Korean facility almost a month ago. Approval should happen any day now. Rolontis is targeting a $3bn+ market. For further details see: Spectrum's Big Approval: Any Day Now

JuSun/iStock via Getty Images After three consecutive days of losses, the small-cap company Spectrum Pharmaceuticals ([[SPPI]] +1.8%) is on the rise in morning hours despite a string of insider selling of its common stock in recent days. Since June 17, the company insiders have offloaded ~38....

Spectrum Pharmaceuticals ([[SPPI]] -1.0%) announced data from an ongoing Phase 2 study for poziotinib in patients with non-small cell lung cancer with EGFR or HER2 exon 20 mutations.The results from the multi-cohort, multi-center study are available in a poster presentation on the w...